Vaxcyte (PCVX): Earnings growth forecast for next year

Vaxcyte Corp (PCVX) - corporate logo

The dynamics of Vaxcyte, Inc. (PCVX) forward EPS estimates demonstrate market earnings expectations, where the value of 15.30 reflects this status. Vaxcyte, Inc. (PCVX) focuses on leadership in anti-infective vaccines, investing in R&D to displace current market behemoths. An impeccable medical reputation confirms its status as a creator of breakthrough drugs. Patent protection and strict FDA regulations create a robust barrier for new entrants.

PCVX - Vaxcyte Inc Projected earnings per share increase next year over the range 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for vaxcyte.com (PCVX)

- share price and consensus valuation forecast:
Stock Price Vaxcyte Corp|PCVX - Average Forecast Price
- stock exchange capitalization data:
Market Capitalization Vaxcyte|PCVX - Real Price to Acquire Entire Company
- book capitalization indicators:
Accounting Value per Share Vaxcyte|PCVX - Total Net Assets|Market Capitalization to Book Value Ratio vaxcyte.com|PCVX - Company Total Asset Base
- company liabilities and liquidity data:
Debt to Equity Vaxcyte, Inc.|PCVX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Vaxcyte|PCVX - Company Aggregate Debt|Debt to Book Capitalization Ratio Vaxcyte|PCVX - Long-Term Debt Volume|Company Current Liabilities Vaxcyte|Quick Ratio vaxcyte.com
- earnings and market ratios statistics:
PCVX - Net Profit|Future Profit Vaxcyte, Inc.|PCVX - Price to Earnings Multiple|Forward P/E Multiple Vaxcyte, Inc.|PCVX - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Vaxcyte|PCVX - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Vaxcyte|PCVX - Earnings per share for the last four quarters|Quarterly EPS earnings growth vaxcyte.com|PCVX - Earnings per share growth rate in current year|Expected earnings per share growth for next year Vaxcyte, Inc.
- sales volume and revenue information:
PCVX - Company Sales Revenue|Projected Sales Volume Vaxcyte Corp|PCVX - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Vaxcyte
General company analysis:PCVX, Vaxcyte Corp
Core merchandise of Vaxcyte

For the biotech sector, where Vaxcyte, Inc. (PCVX) invests liquid reserves into R&D, forward metrics carry more weight than current losses. This projected earnings per share growth benchmark measures the percentage change in expected EPS, allowing investors to assess the timing of the company's transition from the capital burn stage to the commercial realization of vaccines and determine the fair entry risk for the asset.

Competitor analysis

SMMT (Summit Therapeutics Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Moderna Therapeutics MRNA|Earnings growth forecast for next year TARS|Expected earnings per share growth for next year cormedix.com CRMD|Seres Therapeutics, Inc. - Expected earnings per share growth for next year|Projected earnings per share increase next year SPRO (Spero Therapeutics Inc)|Scynexis - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year AN2 Therapeutics, Inc. ANTX|polypid.com (PYPD) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year ysbiopharm.com (LSB)|Net earnings per share growth forecast for next year Iterum Therapeutics PLC|Projected earnings per share growth rate for next year PHGE (BiomX Ltd)|Net earnings per share growth forecast for next year Soligenix, Inc. (SNGX)|Consensus forecast of earnings per share growth for next year 60degreespharma.com|Oragenics - Expected earnings per share growth for next year|opgen.com - Net earnings per share growth forecast for next year